Core Viewpoint - IQVIA Holdings Inc. is identified as one of the most undervalued AI stocks currently available for investment, supported by positive analyst and hedge fund sentiment, as well as a low forward price-to-earnings ratio [1] Financial Performance - For the fourth quarter, IQVIA reported a revenue growth of 10.30%, reaching $4.36 billion [5] - The company's R&D backlog increased to $32.70 billion, with a book-to-bill ratio of 1.18x [5] - Adjusted EPS for the quarter was $3.42, reflecting a 9.60% increase [5] - Looking forward, IQVIA anticipates revenue between $17.15 billion and $17.35 billion, and adjusted EPS between $12.55 and $12.85 [5] Analyst Ratings and Price Targets - Mizuho lowered its price target for IQVIA from $266 to $215 while maintaining an 'Outperform' rating [2] - Truist reduced its price target from $290 to $245 and cut its forward EBITDA multiple from 14x to 13x due to AI-related concerns, while still holding a 'Buy' rating [4]

Core Insights - Broyhill Asset Management's fourth-quarter 2025 investor letter highlights extreme market concentration and a strong focus on artificial intelligence, resulting in many sectors being left behind [1] - The portfolio has been significantly reshaped and now trades at a substantial discount compared to the broader market, with the firm expecting to benefit as market fundamentals improve [1] - The portfolio declined by 1.4% for the year, underperforming the MSCI ACWI's 22.9% return, indicating a market dominated by momentum rather than fundamentals [1] Company Highlights - IQVIA Holdings Inc. (NYSE:IQV) is identified as one of the top contributors to Broyhill's portfolio, recognized for its role as a leading provider of clinical research services and healthcare intelligence [2][3] - As of February 25, 2026, IQVIA's stock closed at $161.91 per share, with a one-month return of -31.28% and a 52-week loss of 13.18%, while its market capitalization stands at $27.573 billion [2] - The company is noted for its durable business model and identifiable catalysts that the market has mispriced, contributing meaningfully as fears around biotech funding and clinical activity began to ease [3] Market Sentiment - Despite IQVIA's potential, it is not among the 30 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, up from 61 in the previous quarter [4] - The sentiment towards the biotech sector remains fragile, but IQVIA's critical role in drug development is considered unchallenged, with expectations for a recovery in the industry [3] - The firm suggests that certain AI stocks may offer greater upside potential and less downside risk compared to IQVIA, indicating a competitive landscape for investment opportunities [4]

Group 1: Company Performance and Financials - IQVIA reported fourth-quarter revenue of $4.36 billion, exceeding the consensus estimate of $4.08 billion [3] - The company achieved near double-digit revenue and EPS growth in 2025, with strong performance across all segments [3] - CEO Ari Bousbib highlighted that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth [3] Group 2: Analyst Ratings and Price Target - Morgan Stanley lowered its price target on IQVIA Holdings Inc. to $240 from $265 but maintained an Overweight rating [1][5] - The adjustment in price target followed the company's quarterly results [1] Group 3: Strategic Collaborations - IQVIA and the Duke Clinical Research Institute announced a collaboration to advance clinical research in obesity and related cardiometabolic trials [2] - The partnership aims to set a new standard for collaboration between life science service companies and academic research organizations, focusing on improving trial efficiency [2]

Core Insights - Optimist Fund reported a return of +9.1% in Q3 2025, outperforming the benchmark return of 7.9% [1] - The fund is focusing on cyclical holdings that have been in multi-year downswings while also paying attention to developments in AI [1] Company Summary: Medpace Holdings, Inc. (NASDAQ:MEDP) - Medpace Holdings, Inc. is a clinical research-based drug and medical device development services provider [2] - The stock of Medpace Holdings, Inc. had a one-month return of 8.99% and gained 81.62% over the last 52 weeks, closing at $580.37 per share with a market capitalization of $16.348 billion on October 30, 2025 [2] - Optimist Fund initiated a position in Medpace in April, viewing it as a market leader with significant long-term growth potential that is currently underappreciated [3] - Medpace reported revenue of $659.9 million in Q3 2025, reflecting a year-over-year increase of 23.7% [4] Investment Perspective - While Medpace is recognized for its potential, the fund suggests that certain AI stocks may offer greater upside potential and less downside risk [4]

Core Viewpoint - Thermo Fisher is acquiring Clario, a privately held data management company, for up to $9.4 billion, which will enhance its clinical trial research business amid a strong rebound in demand [1] Company Summary - The acquisition of Clario is aimed at strengthening Thermo Fisher's position in the clinical trial research sector [1] - The deal reflects a strategic move to capitalize on the increasing demand for clinical trial services [1] Industry Summary - The clinical trial research industry is experiencing a significant rebound in demand, which is driving companies like Thermo Fisher to pursue acquisitions to enhance their service offerings [1]

Core Insights - Medpace reported another strong quarter with significant sales and profit growth, leading to a guidance hike for the full year [2][7][9] Financial Performance - Medpace achieved adjusted earnings of $3.86 per share, exceeding expectations of $3.37, marking a growth of over 28% [7] - Revenue increased nearly 24% to $659.9 million, surpassing forecasts of $641 million, representing the third consecutive quarter of accelerating sales growth [7] - The company secured $789.6 million in new business awards, a 48% increase, resulting in a book-to-bill ratio of 1.2x, outperforming analyst expectations of 1.1x to 1.13x [3][4] Guidance and Outlook - Medpace raised its full-year earnings guidance to a range of $14.60 to $14.86 per share, an increase of approximately 59 cents at the midpoint from previous guidance [9] - The sales forecast was also adjusted to $2.48 billion to $2.53 billion, up from the previous range of $2.42 billion to $2.52 billion [9] Analyst Commentary - Analysts described the quarter as "flawless," with strong pull-through on revenue and new bookings exceeding expectations [2][3] - The significant increase in bookings over the last couple of quarters surprised analysts, indicating a positive trend in the biotech funding environment [5][6]

Core Insights - Headwaters Capital Management's third-quarter 2025 investor letter focused on AI and reported a portfolio return of -2.7% compared to a +5.3% gain for the Russell Mid Cap Index [1] Company Performance - Medpace Holdings, Inc. (NASDAQ:MEDP) was highlighted as a top contributor with a return of +64% in the quarter, driven by strong bookings despite a challenging biotech funding environment [3] - Medpace's stock closed at $527.40 on October 13, 2025, with a market capitalization of $14.816 billion, and it experienced a one-month return of 7.46% and a 49.28% increase over the last 52 weeks [2] - The company reported revenue of $603.3 million in the second quarter of 2025, marking a 14.2% year-over-year increase [4] Investment Strategy - Headwaters Capital Management noted that Medpace's disciplined capital allocation and market share gains make it a core long-term holding, despite the cyclical nature of its end markets [3] - The firm indicated that while Medpace has potential, certain AI stocks may offer greater upside potential with less downside risk [4]

Group 1 - Illumina's stock has dropped by 11% in a week due to increased competition from China's MGI Tech, which is gaining market share in DNA sequencing [2] - MGI Tech's global market presence remains strong despite a recent decline in international sales due to U.S. sanctions [2] - IQVIA presents stronger revenue growth at 5.3% compared to Illumina's decline of 4.8%, indicating a potentially better investment opportunity [3][6] Group 2 - Illumina offers solutions for genomic analysis and sequencing, serving research and clinical markets globally [4] - IQVIA provides advanced analytics and clinical research services, including cloud applications and project management for the life sciences sector [4] - IQVIA's revenue growth for the last 12 months is 3.6%, surpassing Illumina's -3.3%, and IQVIA's average margin is 13.7% compared to Illumina's 6.7% [6]